Business Wire

New Study: Hand Dryers Equally Hygienic to Paper Towels for Drying Hands

Share

After an exhaustive two-year process, a University of Arizona Health Sciences research team have announced the publication of their work, Comparison of electric hand dryers and paper towels for hand hygiene: a critical review of the literature. The review culled the current breadth of data, including published studies, news reports and online content, seeking to uncover which hand drying method, hand dryers or paper towels, is more hygienic and safer relative to human health risks. The researchers found that, while studies in the public arena generally favor paper towels over hand dryers, the conclusions are largely misleading and unsubstantiated.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005927/en/

New study: hand dryers equally hygienic to paper towels for drying hands; Findings support World Health Organization and Centers for Disease Control and Prevention hand washing recommendations (Photo: Business Wire)

New study: hand dryers equally hygienic to paper towels for drying hands; Findings support World Health Organization and Centers for Disease Control and Prevention hand washing recommendations (Photo: Business Wire)

Through the scientific research, the use of hand dryers and paper towels to dry hands were found to be equal from a health and safety perspective; the findings echo recommendations from the World Health Organization that everyone “frequently clean [their] hands…” and “dry [them] thoroughly by using paper towels or a warm air dryer,” and the Centers for Disease Control and Prevention that report that, “Both [clean towels or air hand dryers] are effective ways to dry hands.”

To conduct the study, the research team considered 293 papers and published studies for inclusion in their review, rejecting 270 for failing to meet review criteria or for reporting generalized recommendations without sufficient scientific evidence. The 23 peer-reviewed studies that met the inclusion criteria were categorized and prioritized based on their scientific rigor, a score determined by taking into account such factors as sample size, methodology, data quality and whether or not the study was set up to represent real-world scenarios.

The study that was found to have the highest rigor score was an independent study conducted by the Mayo Clinic, Effects of 4 Hand-Drying Methods for Removing Bacteria From Washed Hands: A Randomized Trial . It found that “…there is no difference in bacteria counts when drying with paper towels or hand dryers.” Only three studies received positive rigor scores for having realistic testing conditions, and none of the studies reported any negative effects of either hand drying method on human health.

Although numerous studies have been published evaluating the “best” method for hand drying, “best” has been defined in a variety of ways relative to bacterial removal efficacy, environmental contamination potentials, ecological or cost benefits, noise and more. Kelly Reynolds, MSPH, Ph.D., the corresponding author of the review explained that, “No study to date has examined the “best” drying method,” and that she and her team, “found no empirical data to support one hand drying method over another from a health and safety perspective.”

In light of the coronavirus pandemic, hand hygiene has been widely covered in the media. Reynolds shared that, “Media reports frequently used sensationalized headlines. While such headlines may increase traffic, they sometimes overgeneralize or exaggerate research results. Consumers may only read the headlines which can influence public opinion toward biased or erroneous conclusions.”

“At a time when proper hand washing and drying is of the utmost importance, exclusively recommending paper towels is limiting, and frankly, irresponsible,” said William Gagnon, vice president of marketing and sales at Excel Dryer. “Hand dryers provide an effective way to achieve completely dry hands, a critical part of proper hand hygiene, the top defense against the spread of germs, like coronavirus.”

The scoping review’s conclusion calls for future studies to examine the relationship between contamination that occurs due to hand-drying methods and human health outcomes. They offer that this can be accomplished by utilizing real-world scenarios while controlling certain variables.

“We hope these credible findings will be consulted as part of guidelines and reopening plans,” said William Gagnon, vice president of marketing and sales at Excel Dryer. “Sensationalized news accounts and click-bait headlines created an unsubstantiated concern around hand dryers and hygiene. We’re grateful to the researchers for uncovering the truth, and hope the findings will help to dispel myths and categorize hand dryers as the hygienic hand drying solution they are.”

About Excel Dryer, Inc.

Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com .

Contact information

Lisa Twarog or Michelle Abdow
(Office) 413-787-1133
ltwarog@marketmentors.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

A Continuous Journey of Digital Transformation, Alibaba Cloud and Its Global Customers at Apsara 202018.9.2020 06:00:00 EESTPress release

As the digital technology and intelligence backbone of Alibaba Group, Alibaba Cloud is experiencing continuous growth alongside its customers across different parts of the world. Over the years, it has made relentless efforts to serve clients from every industry, helping them accelerate their business development and navigate the challenges of these volatile times. Cloud computing and AI technology have been shown to be the cornerstone for businesses seeking to be fully equipped in the digital era, especially following the global outbreak of COVID-19. At the 12th Apsara Conference: Leap into the Future of Digital Intelligence, customers from various sectors, including aviation, leisure and hospitality, education, and e-commerce and retail, share their growth and success stories achieved together with Alibaba Cloud. “It is our utmost pleasure to see our customers experience a seamless transition into more digitalised operations,” said Selina Yuan, President for International Business, A

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer18.9.2020 01:05:00 EESTPress release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), and the first reported data from the pivotal Phase 2 trial of its investigational PARP inhibitor pamiparib in advanced ovarian cancer (OC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which takes place on September 19-21. “We are pleased to share the promising RATIONALE 304 results, which were used to support our recently accepted supplemental new drug application in first-line non-squamous NSCLC in China,” commented Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. “BeiGene is evaluating tislelizuma

Sensorion Launches a Capital Increase by Means of an Accelerated Bookbuild Offering17.9.2020 20:33:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, intends to issue new ordinary shares of a nominal value of €0.10 (the “New Shares”) for a total capital increase of approximately €30 million (US$35 million), by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The New Shares will be issued through a share capital increase without shareholders’ preferential subscription rights pursuant to the 12th resolution of the extraordinary general meeting of shareholders of the Company held on May 20, 2020 and in accordance with Article

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom